{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:16:44Z","timestamp":1790705804386,"version":"4.1.0"},"reference-count":68,"publisher":"Japanese Circulation Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1253\/circj.cj-16-0326","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T22:06:01Z","timestamp":1463090761000},"page":"1285-1291","source":"Crossref","is-referenced-by-count":77,"title":["Catecholaminergic Polymorphic Ventricular Tachycardia"],"prefix":"10.1253","volume":"80","author":[{"given":"Krystien V.","family":"Lieve","sequence":"first","affiliation":[{"name":"Heart Centre, Department of Clinical and Experimental Cardiology, Academic Medical Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"van der Werf","sequence":"additional","affiliation":[{"name":"Heart Centre, Department of Clinical and Experimental Cardiology, Academic Medical Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur A.","family":"Wilde","sequence":"additional","affiliation":[{"name":"Heart Centre, Department of Clinical and Experimental Cardiology, Academic Medical Centre"},{"name":"Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children: A 7-year follow-up of 21 patients. <i>Circulation<\/i> 1995; 91: 1512\u20131519.","DOI":"10.1161\/01.CIR.91.5.1512"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tester DJ, Medeiros-Domingo A, Will ML, Haglund CM, Ackerman MJ. Cardiac channel molecular autopsy: Insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. <i>Mayo Clin Proc<\/i> 2012; 87: 524\u2013539.","DOI":"10.1016\/j.mayocp.2012.02.017"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jim\u00e9nez-J\u00e1imez J, Peinado R, Grima EZ, Segura F, Mori\u00f1a P, S\u00e1nchez Mu\u00f1oz JJ, et al. Diagnostic approach to unexplained cardiac arrest (from the FIVI-Gen Study). <i>Am J Cardiol<\/i> 2015; 116: 894\u2013899.","DOI":"10.1016\/j.amjcard.2015.06.030"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Roston TM, Vinocur JM, Maginot KR, Mohammed S, Salerno JC, Etheridge SP, et al. Catecholaminergic polymorphic ventricular tachycardia in children: Analysis of therapeutic strategies and outcomes from an international multicenter registry. <i>Circ Arrhythm Electrophysiol<\/i> 2015; 8: 633\u2013642.","DOI":"10.1161\/CIRCEP.114.002217"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sy RW, Gollob MH, Klein GJ, Yee R, Skanes AC, Gula LJ, et al. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. <i>Heart Rhythm<\/i> 2011; 8: 864\u2013871.","DOI":"10.1016\/j.hrthm.2011.01.048"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. <i>Circulation<\/i> 2002; 106: 69\u201374.","DOI":"10.1161\/01.CIR.0000020013.73106.D8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. <i>Circulation<\/i> 2009; 119: 2426\u20132434.","DOI":"10.1161\/CIRCULATIONAHA.108.829267"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Berg KJ. Multifocal ventricular extrasytoles with Adams-Stokes syndrome in siblings. <i>Am Heart J<\/i> 1960; 60: 965\u2013970.","DOI":"10.1016\/0002-8703(60)90128-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. van der Werf C, Nederend I, Hofman N, van Geloven N, Ebink C, Frohn-Mulder IME, et al. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: Disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. <i>Circ Arrhythm Electrophysiol<\/i> 2012; 5: 748\u2013756.","DOI":"10.1161\/CIRCEP.112.970517"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Postma AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaksmann G, et al. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. <i>J Med Genet<\/i> 2005; 42: 863\u2013870.","DOI":"10.1136\/jmg.2004.028993"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Neco P, Torrente AG, Mesirca P, Zorio E, Liu N, Priori SG, et al. Paradoxical effect of increased diastolic Ca(2+) release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia. <i>Circulation<\/i> 2012; 126: 392\u2013401.","DOI":"10.1161\/CIRCULATIONAHA.111.075382"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Aizawa Y, Komura S, Okada S, Chinushi M, Aizawa Y, Morita H, et al. Distinct U wave changes in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT). <i>Int Heart J<\/i> 2006; 47: 381\u2013389.","DOI":"10.1536\/ihj.47.381"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sumitomo N, Nakamura T, Fukuhara J, Nakai T, Watanabe I, Mugishima H, et al. Clinical effectiveness of pulmonary vein isolation for arrhythmic events in a patient with catecholaminergic polymorphic ventricular tachycardia. <i>Heart Vessels<\/i> 2010; 25: 448\u2013452.","DOI":"10.1007\/s00380-009-1214-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Di Pino A, Caruso E, Costanzo L, Guccione P. A novel RyR2 mutation in a 2-year-old baby presenting with atrial fibrillation, atrial flutter, and atrial ectopic tachycardia. <i>Heart Rhythm<\/i> 2014; 11: 1480\u20131483.","DOI":"10.1016\/j.hrthm.2014.04.037"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Purohit A, Rokita AG, Guan X, Chen B, Koval OM, Voigt N, et al. Oxidized Ca(2+)\/calmodulin-dependent protein kinase II triggers atrial fibrillation. <i>Circulation<\/i> 2013; 128: 1748\u20131757.","DOI":"10.1161\/CIRCULATIONAHA.113.003313"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Huke S, Knollmann BC. Oxidized CaMKII: A \u201cheart stopper\u201d for the sinus node? <i>J Clin Invest<\/i> 2011; 121: 2975\u20132977.","DOI":"10.1172\/JCI58389"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Faggioni M, Savio-Galimberti E, Venkataraman R, Hwang HS, Kannankeril PJ, Darbar D, et al. Suppression of spontaneous ca elevations prevents atrial fibrillation in calsequestrin 2-null hearts. <i>Circ Arrhythm Electrophysiol<\/i> 2014; 7: 313\u2013320.","DOI":"10.1161\/CIRCEP.113.000994"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Glukhov AV, Kalyanasundaram A, Lou Q, Hage LT, Hansen BJ, Belevych AE, et al. Calsequestrin 2 deletion causes sinoatrial node dysfunction and atrial arrhythmias associated with altered sarcoplasmic reticulum calcium cycling and degenerative fibrosis within the mouse atrial pacemaker complex1. <i>Eur Heart J<\/i> 2015; 36: 686\u2013697.","DOI":"10.1093\/eurheartj\/eht452"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Faggioni M, Hwang HS, van der Werf C, Nederend I, Kannankeril PJ, Wilde AA, et al. Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients. <i>Circ Res<\/i> 2013; 112: 689\u2013697.","DOI":"10.1161\/CIRCRESAHA.111.300076"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lu CW, Lin JH, Rajawat YS, Jerng H, Rami TG, Sanchez X, et al. Functional and clinical characterization of a mutation in KCNJ2 associated with Andersen-Tawil syndrome. <i>J Med Genet<\/i> 2006; 43: 653\u2013659.","DOI":"10.1136\/jmg.2006.040816"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Cerrone M, Noujaim SF, Tolkacheva EG, Talkachou A, O\u2019Connell R, Berenfeld O, et al. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. <i>Circ Res<\/i> 2007; 101: 1039\u20131048.","DOI":"10.1161\/CIRCRESAHA.107.148064"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. HRS\/EHRA\/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: Document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. <i>Heart Rhythm<\/i> 2013; 10: 1932\u20131963.","DOI":"10.1016\/j.hrthm.2013.05.014"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hayashi M, Denjoy I, Extramiana F, Maltret A, Roux-Buisson N, Lupoglazoff J-M, et al. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands. <i>Europace<\/i> 2012; 14: 1344\u20131351.","DOI":"10.1093\/europace\/eus031"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Marjamaa A, Hiippala A, Arrhenius B, Lahtinen AM, Kontula K, Toivonen L, et al. Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia. <i>J Cardiovasc Electrophysiol<\/i> 2012; 23: 194\u2013199.","DOI":"10.1111\/j.1540-8167.2011.02188.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Hofman N, Tan HL, Alders M, Kolder I, de Haij S, Mannens MM, et al. Yield of molecular and clinical testing for arrhythmia syndromes: Report of 15 years\u2019 experience. <i>Circulation<\/i> 2013; 128: 1513\u20131521.","DOI":"10.1161\/CIRCULATIONAHA.112.000091"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS\/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). <i>Europace<\/i> 2011; 13: 1077\u20131109.","DOI":"10.1093\/europace\/eur245"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Swan H, Piippo K, Viitasalo M, Heikkil\u00e4 P, Paavonen T, Kainulainen K, et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. <i>J Am Coll Cardiol<\/i> 1999; 34: 2035\u20132042.","DOI":"10.1016\/S0735-1097(99)00461-1"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. <i>Circulation<\/i> 2001; 103: 196\u2013200.","DOI":"10.1161\/01.CIR.103.2.196"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. <i>Circulation<\/i> 2001; 103: 485\u2013490.","DOI":"10.1161\/01.CIR.103.4.485"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Jiang D, Xiao B, Yang D, Wang R, Choi P, Zhang L, et al. RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca<sup>2+<\/sup> release (SOICR). <i>Proc Natl Acad Sci USA<\/i> 2004; 101: 13062\u201313067.","DOI":"10.1073\/pnas.0402388101"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Knollmann BC, Chopra N, Hlaing T, Akin B, Yang T, Ettensohn K, et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca<sup>2+<\/sup> release, and catecholaminergic polymorphic ventricular tachycardia. <i>J Clin Invest<\/i> 2006; 116: 2510\u20132520.","DOI":"10.1172\/JCI29128"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Jiang D, Chen W, Wang R, Zhang L, Chen SRW. Loss of luminal Ca2+ activation in the cardiac ryanodine receptor is associated with ventricular fibrillation and sudden death. <i>Proc Natl Acad Sci USA<\/i> 2007; 104: 18309\u201318314.","DOI":"10.1073\/pnas.0706573104"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, Hofman N, Bikker H, van Tintelen JP, et al. The RYR2-encoded ryanodine receptor\/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: A comprehensive open reading frame mutation analysis. <i>J Am Coll Cardiol<\/i> 2009; 54: 2065\u20132074.","DOI":"10.1016\/j.jacc.2009.08.022"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Bai R, Napolitano C, Bloise R, Monteforte N, Priori SG. Yield of genetic screening in inherited cardiac channelopathies: How to prioritize access to genetic testing. <i>Circ Arrhythm Electrophysiol<\/i> 2009; 2: 6\u201315.","DOI":"10.1161\/CIRCEP.108.782888"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Bhuiyan ZA, van den Berg MP, van Tintelen JP, Bink-Boelkens MTE, Wiesfeld ACP, Alders M, et al. Expanding spectrum of human RYR2-related disease: New electrocardiographic, structural, and genetic features. <i>Circulation<\/i> 2007; 116: 1569\u20131576.","DOI":"10.1161\/CIRCULATIONAHA.107.711606"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. <i>Am J Hum Genet<\/i> 2001; 69: 1378\u20131384.","DOI":"10.1086\/324565"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Bhuiyan ZA, Hamdan MA, Shamsi ETA, Postma AV, Mannens MM, Wilde AA, et al. A novel early onset lethal form of catecholaminergic polymorphic ventricular tachycardia maps to chromosome 7p14-p22. <i>J Cardiovasc Electrophysiol<\/i> 2007; 18: 1060\u20131066.","DOI":"10.1111\/j.1540-8167.2007.00913.x"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Roux-Buisson N, Cacheux M, Fourest-Lieuvin A, Fauconnier J, Brocard J, Denjoy I, et al. Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. <i>Hum Mol Genet<\/i> 2012; 21: 2759\u20132767.","DOI":"10.1093\/hmg\/dds104"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Nyegaard M, Overgaard MT, S\u00f8ndergaard MT, Vranas M, Behr ER, Hildebrandt LL, et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. <i>Am J Hum Genet<\/i> 2012; 91: 703\u2013712.","DOI":"10.1016\/j.ajhg.2012.08.015"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Crotti L, Johnson CN, Graf E, De Ferrari GM, Cuneo BF, Ovadia M, et al. Calmodulin mutations associated with recurrent cardiac arrest in infants. <i>Circulation<\/i> 2013; 127: 1009\u20131017.","DOI":"10.1161\/CIRCULATIONAHA.112.001216"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Marsman RF, Barc J, Beekman L, Alders M, Dooijes D, van den Wijngaard A, et al. A mutation in CALM1 encoding calmodulin in familial idiopathic ventricular fibrillation in childhood and adolescence. <i>J Am Coll Cardiol<\/i> 2014; 63: 259\u2013266.","DOI":"10.1016\/j.jacc.2013.07.091"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Makita N, Yagihara N, Crotti L, Johnson CN, Beckmann BM, Roh MS, et al. Novel calmodulin mutations associated with congenital arrhythmia susceptibility. <i>Circ Cardiovasc Genet<\/i> 2014; 7: 466\u2013474.","DOI":"10.1161\/CIRCGENETICS.113.000459"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. <i>Nature<\/i> 2003; 421: 634\u2013639.","DOI":"10.1038\/nature01335"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Mohler PJ, Splawski I, Napolitano C, Bottelli G, Sharpe L, Timothy K, et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. <i>Proc Natl Acad Sci USA<\/i> 2004; 101: 9137\u20139142.","DOI":"10.1073\/pnas.0402546101"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Plaster NM, Tawil R, Tristani-Firouzi M, Can\u00fan S, Bendahhou S, Tsunoda A, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen\u2019s syndrome. <i>Cell<\/i> 2001; 105: 511\u2013519.","DOI":"10.1016\/S0092-8674(01)00342-7"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Jabbari J, Jabbari R, Nielsen MW, Holst AG, Nielsen JB, Haunso S, et al. New exome data question the pathogenicity of genetic variants previously associated with catecholaminergic polymorphic ventricular tachycardia. <i>Circ Cardiovasc Genet<\/i> 2013; 6: 481\u2013489.","DOI":"10.1161\/CIRCGENETICS.113.000118"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. T\u00fcl\u00fcmen E, Schulze-Bahr E, Zumhagen S, Stallmeyer B, Seebohm G, Beckmann BM, et al. Early repolarization pattern: A marker of increased risk in patients with catecholaminergic polymorphic ventricular tachycardia. <i>Europace<\/i>2015 December 23, doi:10.1093\/europace\/euv357.","DOI":"10.1093\/europace\/euv357"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Leren IS, Saberniak J, Majid E, Haland TF, Edvardsen T, Haugaa KH. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with \u03b21-selective \u03b2-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. <i>Heart Rhythm<\/i> 2016; 13: 433\u2013440.","DOI":"10.1016\/j.hrthm.2015.09.029"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. van der Werf C, Zwinderman AH, Wilde AA. Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: State of the art and future developments. <i>Europace<\/i> 2012; 14: 175\u2013183.","DOI":"10.1093\/europace\/eur277"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. <i>J Am Coll Cardiol<\/i> 2011; 57: 2244\u20132254.","DOI":"10.1016\/j.jacc.2011.01.026"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. <i>Nat Med<\/i> 2009; 15: 380\u2013383.","DOI":"10.1038\/nm.1942"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Watanabe H, van der Werf C, Roses-Noguer F, Adler A, Sumitomo N, Veltmann C, et al. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. <i>Heart Rhythm<\/i> 2013; 10: 542\u2013547.","DOI":"10.1016\/j.hrthm.2012.12.035"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Khoury A, Marai I, Suleiman M, Blich M, Lorber A, Gepstein L, et al. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. <i>Heart Rhythm<\/i> 2013; 10: 1671\u20131675.","DOI":"10.1016\/j.hrthm.2013.08.011"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Padfield GJ, AlAhmari L, Lieve KV, AlAhmari T, Roston TM, Wilde AA, et al. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of \u03b2-blockade. <i>Heart Rhythm<\/i> 2016; 133: 557\u2013565.","DOI":"10.1016\/j.hrthm.2015.09.027"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Bannister ML, Thomas NL, Sikkel MB, Mukherjee S, Maxwell C, MacLeod KT, et al. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2. <i>Circ Res<\/i> 2015; 116: 1324\u20131335.","DOI":"10.1161\/CIRCRESAHA.116.305347"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Liu N, Denegri M, Ruan Y, Avelino-Cruz JE, Perissi A, Negri S, et al. Flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity [Short communication]. <i>Circ Res<\/i> 2011; 109: 291\u2013295.","DOI":"10.1161\/CIRCRESAHA.111.247338"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Sikkel MB, Collins TP, Rowlands C, Shah M, O\u2019Gara P, Williams AJ, et al. Flecainide reduces Ca(2+) spark and wave frequency via inhibition of the sarcolemmal sodium current. <i>Cardiovasc Res<\/i> 2013; 98: 286\u2013296.","DOI":"10.1093\/cvr\/cvt012"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Smith GL, MacQuaide N. The direct actions of flecainide on the human cardiac ryanodine receptor: Keeping open the debate on the mechanism of action of local anesthetics in CPVT. <i>Circ Res<\/i> 2015; 116: 1284\u20131286.","DOI":"10.1161\/CIRCRESAHA.115.306298"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Odero A, Bozzani A, De Ferrari GM, Schwartz PJ. Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: The surgical supraclavicular approach to cervicothoracic sympathectomy. <i>Heart Rhythm<\/i> 2010; 7: 1161\u20131165.","DOI":"10.1016\/j.hrthm.2010.03.046"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Schwartz PJ. The rationale and the role of left stellectomy for the prevention of malignant arrhythmias. <i>Ann NY Acad Sci<\/i> 1984; 427: 199\u2013221.","DOI":"10.1111\/j.1749-6632.1984.tb20785.x"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. De Ferrari GM, Dusi V, Spazzolini C, Bos JM, Abrams DJ, Berul CI, et al. Clinical management of catecholaminergic polymorphic ventricular tachycardia: The role of left cardiac sympathetic denervation. <i>Circulation<\/i> 2015; 131: 2185\u20132193.","DOI":"10.1161\/CIRCULATIONAHA.115.015731"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. <i>Circulation<\/i> 2004; 109: 1826\u20131833.","DOI":"10.1161\/01.CIR.0000125523.14403.1E"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Mohamed U, Gollob MH, Gow RM, Krahn AD. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. <i>Heart Rhythm<\/i> 2006; 3: 1486\u20131489.","DOI":"10.1016\/j.hrthm.2006.08.018"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Palanca V, Quesada A, Trigo A, Jim\u00e9nez J. Arrhythmic storm induced by AICD discharge in a patient with catecholaminergic polymorphic ventricular tachycardia. <i>Rev Espa\u00f1ola Cardiol<\/i> 2006; 59: 1079\u20131080 (in Spanish).","DOI":"10.1157\/13093988"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Miyake CY, Webster G, Czosek RJ, Kantoch MJ, Dubin AM, Avasarala K, et al. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: Success depends on substrate. <i>Circ Arrhythm Electrophysiol<\/i> 2013; 6: 579\u2013587.","DOI":"10.1161\/CIRCEP.113.000170"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Roses-Noguer F, Jarman JWE, Clague JR, Till J. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. <i>Heart Rhythm<\/i> 2014; 11: 58\u201366.","DOI":"10.1016\/j.hrthm.2013.10.027"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Olde Nordkamp LRA, Postema PG, Knops RE, van Dijk N, Limpens J, Wilde AAM, et al. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications. <i>Heart Rhythm<\/i> 2016; 13: 443\u2013454.","DOI":"10.1016\/j.hrthm.2015.09.010"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Denegri M, Bongianino R, Lodola F, Boncompagni S, De Giusti VC, Avelino-Cruz JE, et al. Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age. <i>Circulation<\/i> 2014; 129: 2673\u20132681.","DOI":"10.1161\/CIRCULATIONAHA.113.006901"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/80\/6\/80_CJ-16-0326\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T13:34:25Z","timestamp":1498311265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/80\/6\/80_CJ-16-0326\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-16-0326","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}